Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by mercedesmanon Feb 29, 2024 4:24pm
126 Views
Post# 35907579

RE:RE:Baxter ramping up hiring for Vantive

RE:RE:Baxter ramping up hiring for Vantive

Thx for digging in on this g 

Looks like Vantive has the green light and that the July timeframe IS still the goal 

I have acquired some Baxter shares in the low 40's and low 30's. Spin-offs are usually shareholder positive events ( if you time them right) - as the sum of the parts can be worth more than the whole. 

Plus although the Vantive spin-off is expected to generate $4.5B in annual sales, wait til it sinks in that with PMX, Vantive revenues could conceivably grow by $2B /year within 5 years. My calculator says that's a 50% growth possibility ( rounded:) 
Shareholders and would be  shareholders will pay up, in advance, for that kind of growth potential. 
Especially in the US where they celebrate their Biotechs  


MM 

<< Previous
Bullboard Posts
Next >>